Definium Therapeutics (NASDAQ:DFTX) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Definium Therapeutics (NASDAQ:DFTX) announced its earnings results on Monday. The company reported ($0.46) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.09, FiscalAI reports.

Here are the key takeaways from Definium Therapeutics’ conference call:

• DT120 delivered positive Phase III results in GAD and MDD across three studies, with rapid, durable improvements and generally good tolerability. The results earned the program FDA breakthrough therapy designations in both indications.
• Definium remains on track to file an NDA for DT120 in the first half of 2027 and is preparing for a potential launch. However, the company did not disclose details of its FDA meeting or its filing strategy for MDD, where a second Phase III study, Ascend, is still underway.
• The company reported approximately $1.05 billion in cash, equivalents, and investments at quarter-end, which it expects to fund operations into 2030. R&D and G&A expenses increased year over year as Definium expanded development and commercial-readiness efforts.
• Early DT402 results in autism spectrum disorder showed improvements across several social and functional measures, prompting the company to stop enrollment after five participants and plan a multi-day dosing study for 2027. The findings are preliminary, coming from a small, open-label study.
• Definium is developing its supervised-treatment launch infrastructure and cited payer feedback indicating a potential pricing corridor of $30,000 to $75,000. Management said more payer discussions are needed to narrow that range and emphasized that provider readiness, access, and patient support will be important to adoption.

Definium Therapeutics Stock Performance

Shares of DFTX stock opened at $35.35 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The company has a market capitalization of $4.75 billion, a price-to-earnings ratio of -10.31 and a beta of 2.23. Definium Therapeutics has a one year low of $10.46 and a one year high of $49.70. The company’s 50-day moving average is $36.49 and its 200 day moving average is $30.05.

Analyst Upgrades and Downgrades

Several brokerages have commented on DFTX. Bank of America started coverage on shares of Definium Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $75.00 price objective for the company. Robert W. Baird increased their target price on Definium Therapeutics from $75.00 to $79.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 15th. Royal Bank Of Canada restated an “outperform” rating on shares of Definium Therapeutics in a research report on Monday, October 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Definium Therapeutics in a research note on Thursday, October 15th. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 price objective on shares of Definium Therapeutics in a research report on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $66.00.

Insider Activity

In related news, CEO Robert Barrow sold 31,550 shares of the stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $1,153,783.50. Following the sale, the chief executive officer directly owned 2,213,090 shares of the company’s stock, valued at $80,932,701.30. This trade represents a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Sullivan sold 14,051 shares of Definium Therapeutics stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $513,845.07. Following the completion of the sale, the insider owned 494,228 shares of the company’s stock, valued at $18,073,917.96. The trade was a 2.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 71,098 shares of company stock worth $2,626,115 over the last three months. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. HighTower Advisors LLC boosted its stake in shares of Definium Therapeutics by 10.3% in the 3rd quarter. HighTower Advisors LLC now owns 24,619 shares of the company’s stock worth $937,000 after buying an additional 2,306 shares during the last quarter. Bessemer Group Inc. purchased a new stake in Definium Therapeutics during the third quarter valued at $42,000. Royce & Associates LP lifted its holdings in Definium Therapeutics by 20.1% in the third quarter. Royce & Associates LP now owns 250,547 shares of the company’s stock valued at $9,536,000 after acquiring an additional 41,996 shares during the period. Aberdeen Group plc lifted its holdings in Definium Therapeutics by 10.0% in the third quarter. Aberdeen Group plc now owns 192,415 shares of the company’s stock valued at $7,323,000 after acquiring an additional 17,415 shares during the period. Finally, Money Concepts Capital Corp boosted its position in Definium Therapeutics by 7.7% in the third quarter. Money Concepts Capital Corp now owns 14,000 shares of the company’s stock worth $533,000 after purchasing an additional 1,000 shares during the last quarter. 27.91% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Definium said it will present Phase 3 DT120 data at the NEI Congress. The presentations could raise awareness of the late-stage program, although no results or conclusions are provided in the announcement. Definium Announces DT120 Phase 3 Data Presentations at NEI Congress
• Positive Sentiment: For the third quarter, Definium reported a loss of $0.46 per share, beating the consensus estimate of a $0.55 loss by $0.09. The earnings surprise may support sentiment, though the company remains loss-making. Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights
• Neutral Sentiment: Definium granted options to buy 269,800 shares to ten new employees. The awards support hiring, while adding potential share dilution; the announcement does not indicate a material near-term financial impact. Definium Therapeutics Announces New Employee Inducement Grants

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.